Patents by Inventor Ralph A. Zingaro
Ralph A. Zingaro has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20130143950Abstract: The present invention provides organic arsenicals which may be used to treat numerous human tumor cell lines, both of solid and hematological origin, as well as against malignant blood cells from patients with leukemia.Type: ApplicationFiled: July 3, 2012Publication date: June 6, 2013Inventor: Ralph A. ZINGARO
-
Patent number: 8222440Abstract: The present invention provides organic arsenicals which may be used to treat numerous human tumor cell lines, both of solid and hematological origin, as well as against malignant blood cells from patients with leukemia.Type: GrantFiled: January 16, 2007Date of Patent: July 17, 2012Assignee: The Texas A&M University SystemInventor: Ralph A. Zingaro
-
Patent number: 7619000Abstract: Arsenic trioxide, an inorganic compound, is commercially available anti-cancer agent but it carries significant toxicity. Organic arsenicals, on the other hand, are much less toxic, to the extent that the methylation of inorganic arsenic in vivo into organic arsenicals has been considered a detoxification reaction. New organic arsenic derivatives have been synthesized, including S-dimethylarsino-glutathione, S-dimethylarsino-thiosuccinic acid and S-dimethylarsino-thiobenzoic acid, and established its potent in vitro cytotoxic activity against numerous human tumor cell lines, both of solid and hematological origin, as well as against malignant blood cells from patients with leukemia. Results form a basis for the development of S-dimethylarsino-glutathione, S-dimethylarsino-thiosuccinic acid, S-dimethylarsino-thiobenzoic acid, and other organic arsenicals as an anti-cancer therapy, combining high efficacy with very low, if any, toxicity.Type: GrantFiled: February 6, 2006Date of Patent: November 17, 2009Assignees: The Texas A&M University System, Board of Regents, The University of Texas SystemInventors: Ralph A. Zingaro, Emil J. Freireich, Hatice Duzkale, Hagop Kantarjian, Srdan Verstovsek, Merida Sotelo-Lerma
-
Publication number: 20090233894Abstract: The present invention provides organic arsenicals which may be used to treat numerous human tumor cell lines, both of solid and hematological origin, as well as against malignant blood cells from patients with leukemia.Type: ApplicationFiled: January 16, 2007Publication date: September 17, 2009Applicant: The Texas A&M University SystemInventor: Ralph A. Zingaro
-
Patent number: 7405314Abstract: The present invention provides organic arsenicals. Many of these compounds have potent in vitro cytotoxic activity against numerous human tumor cell lines, both of solid and hematological origin, as well as against malignant blood cells from patients with leukemia.Type: GrantFiled: October 17, 2005Date of Patent: July 29, 2008Assignees: The Texas A&M University System, Board of Regents, The University of Texas SystemInventors: Ralph A. Zingaro, Hatice Duzkale, Emil J. Freireich, Hagop Kantarjian, Merida Sotelo-Lerma, Srdan Verstovsek, Mingzhang Gao
-
Publication number: 20080090904Abstract: Arsenic trioxide, an inorganic compound, is commercially available anti-cancer agent but it carries significant toxicity. Organic arsenicals, on the other hand, are much less toxic, to the extent that the methylation of inorganic arsenic in vivo into organic arsenicals has been considered a detoxification reaction. New organic arsenic derivatives have been synthesized, including S-dimethylarsino-glutathione, S-dimethylarsino-thiosuccinic acid and S-dimethylarsino-thiobenzoic acid, and established its potent in vitro cytotoxic activity against numerous human tumor cell lines, both of solid and hematological origin, as well as against malignant blood cells from patients with leukemia. Results form a basis for the development of S-dimethylarsino-glutathione, S-dimethylarsino-thiosuccinic acid, S-dimethylarsino-thiobenzoic acid, and other organic arsenicals as an anti-cancer therapy, combining high efficacy with very low, if any, toxicity.Type: ApplicationFiled: August 20, 2007Publication date: April 17, 2008Applicants: The Texas A&M University System, Board of Regents, The University of Texas SystemInventors: Ralph Zingaro, Emil Freireich, Hatice Duzkale, Hagop Kantarjian, Srdan Verstovsek, Merida Sotelo-Lerma
-
Publication number: 20080090793Abstract: The present invention provides organic arsenicals. Many of these compounds have potent in vitro cytotoxic activity against numerous human tumor cell lines, both of solid and hematological origin, as well as against malignant blood cells from patients with leukemia.Type: ApplicationFiled: August 20, 2007Publication date: April 17, 2008Applicants: The Texas A&M University System, Board of Regents, The University of Texas SystemInventors: Ralph Zingaro, Hatice Duzkale, Emil Freireich, Hagop Kantarjian, Merida Sotelo-Lerma, Srdan Verstovsek, Mingzhang Gao
-
Publication number: 20060189687Abstract: Arsenic trioxide, an inorganic compound, is commercially available anti-cancer agent but it carries significant toxicity. Organic arsenicals, on the other hand, are much less toxic, to the extent that the methylation of inorganic arsenic in vivo into organic arsenicals has been considered a detoxification reaction. New organic arsenic derivatives have been synthesized, including S-dimethylarsino-glutathione, S-dimethylarsino-thiosuccinic acid and S-dimethylarsino-thiobenzoic acid, and established its potent in vitro cytotoxic activity against numerous human tumor cell lines, both of solid and hematological origin, as well as against malignant blood cells from patients with leukemia. Results form a basis for the development of S-dimethylarsino-glutathione, S-dimethylarsino-thiosuccinic acid, S-dimethylarsino-thiobenzoic acid, and other organic arsenicals as an anti-cancer therapy, combining high efficacy with very low, if any, toxicity.Type: ApplicationFiled: February 6, 2006Publication date: August 24, 2006Applicants: The Texas A&M University System, Board of Regents, The University of Texas SystemInventors: Ralph Zingaro, Emil Freireich, Hatice Duzkale, Hagop Kantarjian, Srdan Verstovsek, Merida Sotelo-Lerma
-
Publication number: 20060128682Abstract: The present invention provides organic arsenicals. Many of these compounds have potent in vitro cytotoxic activity against numerous human tumor cell lines, both of solid and hematological origin, as well as against malignant blood cells from patients with leukemia.Type: ApplicationFiled: October 17, 2005Publication date: June 15, 2006Applicants: The Texas A&M University System, Board of Regents, The University of Texas SystemInventors: Ralph Zingaro, Hatice Duzkale, Emil Freireich, Hagop Kantarjian, Merida Sotelo-Lerma, Srdan Verstovsek, Mingzhang Gao
-
Patent number: 6995188Abstract: Arsenic trioxide, an inorganic compound, is commercially available anti-cancer agent but it carries significant toxicity. Organic arsenicals, on the other hand, are much less toxic, to the extent that the methylation of inorganic arsenic in vivo into organic arsenicals has been considered a detoxification reaction. New organic arsenic derivatives have been synthesized, including S-dimethylarsino-glutathione, S-dimethylarsino-thiosuccinic acid and S-dimethylarsino-thiobenzoic acid, and established its potent in vitro cytotoxic activity against numerous human tumor cell lines, both of solid and hematological origin, as well as against malignant blood cells from patients with leukemia. Results form a basis for the development of S-dimethylarsino-glutathione, S-dimethylarsino-thiosuccinic acid, S-dimethylarsino-thiobenzoic acid, and other organic arsenicals as an anti-cancer therapy, combining high efficacy with very low, if any, toxicity.Type: GrantFiled: January 13, 2005Date of Patent: February 7, 2006Assignees: Board of Regents, The University of Texas System, The Texas A&M University SystemInventors: Ralph A. Zingaro, Emil J. Freireich, Hatice Duzkale, Hagop Kantarjian, Srdan Verstovsek, Merida Sotelo-Lerma
-
Patent number: 6911471Abstract: Arsenic trioxide, an inorganic compound, is commercially available anti-cancer agent but it carries significant toxicity. Organic arsenicals, on the other hand, are much less toxic, to the extent that the methylation of inorganic arsenic in vivo into organic arsenicals has been considered a detoxification reaction. New organic arsenic derivatives have been synthesized, including S-dimethylarsino-glutathione, S-dimethylarsino-thiosuccinic acid and S-dimethylarsino-thiobenzoic acid, and established its potent in vitro cytotoxic activity against numerous human tumor cell lines, both of solid and hematological origin, as well as against malignant blood cells from patients with leukemia. Results form a basis for the development of S-dimethylarsino-glutathione, S-dimethylarsino-thiosuccinic acid, S-dimethylarsino-thiobenzoic acid, and other organic arsenicals as an anti-cancer therapy, combining high efficacy with very low, if any, toxicity.Type: GrantFiled: January 7, 2003Date of Patent: June 28, 2005Assignees: The Texas A&M University System, Board of Regents, The University of Texas SystemInventors: Ralph A. Zingaro, Emil J. Freireich, Hatice Duzkale, Hagop Kantarjian, Srdan Verstovsek, Merida Sotelo-Lerma
-
Publication number: 20050131062Abstract: Arsenic trioxide, an inorganic compound, is commercially available anti-cancer agent but it carries significant toxicity. Organic arsenicals, on the other hand, are much less toxic, to the extent that the methylation of inorganic arsenic in vivo into organic arsenicals has been considered a detoxification reaction. New organic arsenic derivatives have been synthesized, including S-dimethylarsino-glutathione, S-dimethylarsino-thiosuccinic acid and S-dimethylarsino-thiobenzoic acid, and established its potent in vitro cytotoxic activity against numerous human tumor cell lines, both of solid and hematological origin, as well as against malignant blood cells from patients with leukemia. Results form a basis for the development of S-dimethylarsino-glutathione, S-dimethylarsino-thiosuccinic acid, S-dimethylarsino-thiobenzoic acid, and other organic arsenicals as an anti-cancer therapy, combining high efficacy with very low, if any, toxicity.Type: ApplicationFiled: January 13, 2005Publication date: June 16, 2005Applicants: The Texas A&M University System, Board of Regents, The University of Texas SystemInventors: Ralph Zingaro, Emil Freireich, Hatice Duzkale, Hagop Kantarjian, Srdan Verstovsek, Merida Sotelo-Lerma
-
Publication number: 20040034095Abstract: Arsenic trioxide, an inorganic compound, is commercially available anti-cancer agent but it carries significant toxicity. Organic arsenicals, on the other hand, are much less toxic, to the extent that the methylation of inorganic arsenic in vivo into organic arsenicals has been considered a detoxification reaction. New organic arsenic derivatives have been synthesized, including S-dimethylarsino-glutathione, S-dimethylarsino-thiosuccinic acid and S-dimethylarsino-thiobenzoic acid, and established its potent in vitro cytotoxic activity against numerous human tumor cell lines, both of solid and hematological origin, as well as against malignant blood cells from patients with leukemia. Results form a basis for the development of S-dimethylarsino-glutathione, S-dimethylarsino-thiosuccinic acid, S-dimethylarsino-thiobenzoic acid, and other organic arsenicals as an anti-cancer therapy, combining high efficacy with very low, if any, toxicity.Type: ApplicationFiled: January 7, 2003Publication date: February 19, 2004Inventors: Ralph A. Zingaro, Emil J. Freireich, Hatice Duzkale, Hagop Kantarjian, Srdan Verstovsek, Merida Sotelo-Lerma